company background image
PJ2 logo

Liminal BioSciences DB:PJ2 Stock Report

Last Price

€3.80

Market Cap

€11.8m

7D

0%

1Y

-0.7%

Updated

02 May, 2023

Data

Company Financials +

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

PJ2 Stock Overview

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom.

PJ2 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Liminal BioSciences Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Liminal BioSciences
Historical stock prices
Current Share Price€3.80
52 Week High€5.32
52 Week Low€0.065
Beta30.72
1 Month Change0%
3 Month Change0%
1 Year Change-0.73%
3 Year Change-94.79%
5 Year Change-99.92%
Change since IPO-99.81%

Recent News & Updates

Recent updates

Shareholder Returns

PJ2DE BiotechsDE Market
7D0%2.1%1.9%
1Y-0.7%37.0%7.3%

Return vs Industry: PJ2 exceeded the German Biotechs industry which returned -7.6% over the past year.

Return vs Market: PJ2 exceeded the German Market which returned -4.5% over the past year.

Price Volatility

Is PJ2's price volatile compared to industry and market?
PJ2 volatility
PJ2 Average Weekly Movementn/a
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: PJ2 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine PJ2's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1994n/aBruce Pritchardhttps://www.liminalbiosciences.com

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage.

Liminal BioSciences Inc. Fundamentals Summary

How do Liminal BioSciences's earnings and revenue compare to its market cap?
PJ2 fundamental statistics
Market cap€11.80m
Earnings (TTM)-€19.54m
Revenue (TTM)€269.81k

43.7x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PJ2 income statement (TTM)
RevenueCA$401.00k
Cost of RevenueCA$15.30m
Gross Profit-CA$14.90m
Other ExpensesCA$14.14m
Earnings-CA$29.04m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-9.35
Gross Margin-3,714.96%
Net Profit Margin-7,241.40%
Debt/Equity Ratio0%

How did PJ2 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.